Sangamo Therapeutics Inc (LTS:0R1D)
$ 1.9196 -0.0403 (-2.06%) Market Cap: 417.29 Mil Enterprise Value: 405.82 Mil PE Ratio: 0 PB Ratio: 10.37 GF Score: 34/100

Q3 2022 Sangamo Therapeutics Inc Earnings Call Transcript

Nov 03, 2022 / 08:30PM GMT
Release Date Price: $4.26 (-3.60%)
Operator

Good day, and thank you for standing by. Welcome to the Sangamo Therapeutics Third Quarter Earnings Call. (Operator Instructions) Please be advised that this call is being recorded.

I will now turn it over to Louise Wilkie, Head of Corporate Communications and Investor Relations. Please go ahead.

Louise Wilkie

Good afternoon. I'm Louise Wilkie, Sangamo's Vice President of Investor Relations and Corporate Communications. Thank you for joining us on the call today. On this call are several members of Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Operating Officer; Prathyusha Duraibabu, Chief Financial Officer; Jason Fontenot, Chief Scientific Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Bettina Cockroft, Chief Medical Officer.

Slides from our corporate presentation can be found on our website, angamo.com, under the Investors & Media section on the Events and Presentations page. This call includes forward-looking statements regarding Sangamo's current expectations.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot